NCT01260961View on ClinicalTrials.gov

Developing Treatment, Treatment Validation and Treatment Scope in the Setting of an Autism Clinical Trial

NAActive, not recruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

July 31, 2015

Study Completion Date

December 1, 2025

Conditions
Autism
Interventions
DIETARY_SUPPLEMENT

Placebo

The volunteers will start on the 200 mg daily of the placebo and will not increase their dose during the study.

DIETARY_SUPPLEMENT

Docosahexanoic Acid

The volunteers will start on the 200 mg daily of the DHA capsule and will not increase their dose during the study.

Trial Locations (1)

08854

Rutgers, Piscataway

All Listed Sponsors
lead

Rutgers, The State University of New Jersey

OTHER

NCT01260961 - Developing Treatment, Treatment Validation and Treatment Scope in the Setting of an Autism Clinical Trial | Biotech Hunter | Biotech Hunter